Dr. Randy Schatzman, CEO at Bolt Biotherapeutics, discusses his company's adjustment to pandemic disruption on the fundraising trail. He walks us through the remote fundraising strategy that landed Bolt a recent $93.5 million Series C financing round, as well as how the company is moving toward an IPO in spite of market, civil, and political tumult.
|